# Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

> **NCT05286437** · PHASE2 · RECRUITING · sponsor: **National Cancer Centre, Singapore** · enrollment: 40 (estimated)

## Conditions studied

- Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

## Interventions

- **DRUG:** Oral Lenvatinib + Intravenous (IV) Pembrolizumab + Oral Letrozole

## Key facts

- **NCT ID:** NCT05286437
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286437, "Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05286437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*